Gene Therapy for Leber's Congenital Amaurosis is Safe and Effective Through 1.5 Years After Vector Administration
Francesca Simonelli(University of Naples Federico II), Alberto Auricchio(Federico II University Hospital), Jeannette Bennicelli(Penn Presbyterian Medical Center), Sandro Banfi(Telethon Institute Of Genetics And Medicine), T. Michael Redmond(National Institutes of Health), Eric A. Pierce(Massachusetts Eye and Ear Infirmary), Federico Mingozzi(Inserm), Francesco Testa(University of Naples Federico II), Jean Bennett(Penn Presbyterian Medical Center), Junwei Sun(Singapore Management University), Katherine A. High(Spark Therapeutics (United States)), J. Fraser Wright(Oxford BioMedica (United Kingdom)), Xiaosong Zhu(Linyi People's Hospital), Gui‐Shuang Ying(Philadelphia College of Osteopathic Medicine), Albert M. Maguire(Children's Hospital of Philadelphia), Carmela Acerra(University of Naples Federico II), Enrico Maria Surace(Telethon Institute Of Genetics And Medicine), Settimio Rossi(University of Naples Federico II), Kathleen Marshall(Children's Hospital of Philadelphia), Carmela Ziviello(Institute of Genetics and Biophysics), Jennifer Wellman McDonnell(Children's Hospital of Philadelphia), Kenneth S. Shindler(Penn Presbyterian Medical Center)
Cited by 551
Related Papers
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
|Ophthalmology|2012|1.7k
Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1
|Nature Genetics|1993|1.7k
Gene therapy comes of age
|Science|2018|1.4k
Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins.
|Proceedings of the National Academy of Sciences|1995|1.3k